DE
| EN
Home
Company
Business areas
Goals
Team
Network
Quality management
Integrated QMS
Certificates
Services
Synthesis development
GMP API manufacturing
Active ingredients for clinical samples
Reference standards
In-vitro diagnostics
Quality control
Advice/Consulting
News
zurück
weiter
News of the HAPILA GmbH
06/17/2024
HAPILA brings advanced API and synthesis capabilities to Chemspec Europe 2024
HAPILA GmbH (HAPILA) will return for the seventh successive time to the influential Chemspec Europe trade show, this time in Düsseldorf, Germany. HAP…
06/13/2024
HAPILA overcomes supply bottlenecks to synthesize anti-TB API agent BTZ-043 for clinical trials
HAPILA GmbH has overcome global supply disruptions to complete its synthesis campaign to produce the required 150 kilos of its innovative…
10/21/2023
HAPILA bringing end-to-end API supply chain solutions to CPHI Barcelona
Gera, Germany: - High-potency active ingredient specialist CDMO HAPILA GmbH is returning to Europe’s leading pharma industry event, the CPHI 2023…
09/20/2023
HAPILA and ATHANA alliance receive funding for nanoparticle antifungal program
The ATHANA alliance that unites key players in the Thuringia life sciences cluster, including HAPILA GmbH, has attracted significant new German…
06/14/2023
HAPILA’s co-developed anti-TB agent BTZ-043 named ‘Drug of the Year’
The small molecule anti-tuberculosis active ingredient BTZ-043 has been named ‘Drug of the Year’ by the Leibniz Wirkstofftage, the Leibniz Research…
© 2024 HAPILA GmbH
